AH declares grants and personal fees from Amgen, BMS, Merck, Pfizer, MSD/Merck, Philogen, Pierre Fabre, Regeneron, Roche, Sanofi-Genzyme, Novartis, Eisai, Immunocore, Replimune, Seagen, IO Biotech, Dermagnostix, Incyte, NeraCare, Huya Biosciences, Kyowa Kirin, Highlight Therapeutics, Iovance, CureVac, Xenthera, Agenus, Almirall, and Sun Pharma outside the submitted work. CG declares consulting fees from Asylia, CeCaVa, MSD, NeraCare, and Philogen, and a leadership role as President of the European Association of Dermatooncology (EADO). PAA declares grants or contracts from BMS, Roche-Genentech, Pfizer, and Sanofi; consulting fees from multiple entities, including BMS, Roche-Genentech, MSD, Novartis, Pierre Fabre, Sun Pharma, Sanofi, Pfizer, and others; travel support from Pfizer, Bio-Al Health, Replimmune, MSD, Pierre Fabre, and Philogen; and participation on data safety monitoring boards or advisory boards for BMS, Roche-Genentech, MSD, Novartis, Boehringer-Ingelheim, Regeneron, Nouscom, Erasca, and Anaveon. LD declares grants, honoraria for lectures, and consulting fees from BIOCAD; serves on BIOCAD's advisory board; and holds an unpaid leadership role in MelanomaPro. BD declares consulting fees and honoraria from Janssen, BMS, and Almirall. RD reports consulting and advisory relationships with Novartis, MSD, BMS, Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, Catalym, Second Genome, Regeneron, T3 Pharma, MaxiVAX SA, Pfizer, and Simcere outside the submitted work. AE declares consulting fees and honoraria for advisory board roles from multiple entities, including Agenus, BioNTech, Boehringer-Ingelheim, Pfizer, and MSD; stock and equity in IO Biotech, Sairopa BV, and SkylineDX BV; and honoraria for presentations on melanoma and immunotherapy development from MSD. AMF declares unpaid roles in EADO and the European Academy of Dermatology and Venereology. CG declares research support from BMS, Novartis, Pierre Fabre, Regeneron, and Sanofi; advisory roles with BMS, Delcath, Immatics, Immunocore, Iovance, MSD, Novartis, Pierre Fabre, Sanofi, Sun Pharma, and Sysmex; honoraria from BMS, Delcath, Immunocore, Medscape, MSD, Novartis, Onkowissen, Pierre Fabre, Regeneron, Sanofi, Sun Pharma, and Sysmex; travel support from BMS, Pierre Fabre, and Sun Pharma; board memberships with DeCOG, the German Skin Cancer Foundation, and the Roggenbuck Foundation; and is co-founder and shareholder of Dermagnostix and Dermagnostix R&D. JEG reports consulting fees from Merck; participation on Merck's data safety monitoring board; a volunteer role as Vice Chair of the American Joint Committee on Cancer and Chair of its Executive Committee; and co-authorship on UpToDate. OH declares consulting fees from Alkermes, Amgen, Bactonix, Beigene, Bioatla, BMS, Eisai, Biotech, Roche, Genentech, Georgiamune, GigaGen, Grit Bio, GSK, Idera, Immunocore, Incyte, Instilbio, IO Biotech, Iovance, Janssen, KSQ, Merck, Moderna, NGM Bio, Novartis, Obsidian, Pfizer, Regeneron, Sanofi, Seattle Genetics, Tempus, Vial Health Tech, and Zelluna; honoraria from BMS, Immunocore, Novartis, Pfizer, and Regeneron; travel support from Alkermes, Amgen, Bactonix, Beigene, Bioatla, BMS, Eisai, Biotech, Roche, Genentech, Georgiamune, GigaGen, Grit Bio, GSK, Idera, Immunocore, Incyte, Instilbio, IO Biotech, Iovance, Janssen, KSQ, Merck, Moderna, NGM Bio, Novartis, Obsidian, Pfizer, Regeneron, Sanofi, Seattle Genetics, Tempus, Vial Health Tech, and Zelluna; and participation on data safety monitoring boards or advisory boards for the same entities. CH declares a research grant to their institution from Amgen; consulting fees from Almirall, BMS, Immunocore, MSD, Novartis, Pierre Fabre, Sanofi, and Ultimovacs; honoraria from AbbVie, Amgen, BMS, MSD, Novartis, Pierre Fabre, Regeneron, and Sanofi; and travel support via their institution from BMS, MSD, and Pierre Fabre. LK declares consulting fees from MSD, Merck, AbbVie, and Janssen; honoraria from BMS, MSD, Novartis, Merck, Roche, AbbVie, and Janssen; and travel support from BMS, MSD, Novartis, and Janssen. RK declares institutional grants for clinical trials from AbbVie, Allakos, Almirall, Amgen, Argenx, AstraZeneca, Boehringer-Ingelheim, Biontech, Bioprojet, BMS, Celldex, Concert Pharma, DICE Therapeutics, Evelo Biosciences, the Fraunhofer Institut, Galderma, Incyte, InflaRx, Innate Pharma, IO Biotech, Janssen, Leo Pharma, Eli Lilly, Moonlake, MSD, Novartis, Numab, Origimm, Pascoe, Pfizer, Regeneron, Roche, Sanofi, and UCB. JMK declares grants from Amgen, BMS, Checkmate Pharmaceuticals, Harbour BioMed, Immvira Pharma, Immunocore, Iovance Biotherapeutics, Lion Biotechnologies, Lytix Biopharma, Novartis, and Takeda; institutional grants from Verastem; consulting fees from Ankyra Therapeutics, Applied Clinical Intelligence, Becker Pharmaceutical Consulting, Boxer Capital, BMS, Checkmate Pharmaceuticals, CytomX Therapeutics, DermTech, Engage Health Media, Fenix Group International, iOnctura, Iovance Biotherapeutics, Istari Oncology, Jazz Pharmaceuticals, Magnolia Innovation, Merck, Natera, Novartis, Oncocyte Corporation, PathAI, Pfizer, Piper Sandler, PyrOjas, Regeneron Pharmaceuticals, Replimune, Scopus BioPharma, and Takeda; personal fees from Valar Labs; honoraria from BMS IO Unbranded Presentations (personal); travel support from Regeneron, Ankyra, Iovance, and Checkmate (personal); advisory roles with Axio Research, IQVIA, and Lytix Biopharma (personal); and leadership roles with AIM at Melanoma Foundation, Cancer Network, Cancer Study Group, OncLive, the Conquer Cancer Foundation, Leidos, the National Cancer Center, the National Cancer Institute, and PRIME Education (all personal payments). CL declares support from BMS, Pierre Fabre, Sanofi, Novartis, MSD, Amgen, Merck Serono, Inflax, and Roche; consulting fees from BMS, Pierre Fabre, Sanofi, Novartis, MSD, Amgen, Merck Serono, Inflax, and Roche; honoraria from Amgen, BMS, Pierre Fabre, Sanofi, Novartis, MSD, Incyte, Pfizer, and Roche; travel support from BMS, MSD, Novartis, Pierre Fabre, Roche, and Sanofi; and research funding from BMS and Roche (institutional). GVL declares consulting fees from Agenus, Amgen, Array Biopharma, AstraZeneca, Bayer Health Care, BioNTech, Boehringer-Ingelheim, BMS, Evaxion Biotech, Hexal AG (Sandoz Company), Highlight Therapeutics, IO Biotech, Immunocore Ireland, Innovent Biologics USA, MSD, Novartis, PHMR, Pierre Fabre, Qbiotics Group, Regeneron Pharmaceuticals, Scancell, and SkylineDX; honoraria from BMS and Pierre Fabre for lectures; and advisory board participation for the same entities as the consulting fees. JM declares honoraria for lectures from Almirall, Sun Pharma, and Pierre Fabre and institutional grants from Sun Pharma, Phylogen, Pierre Fabre, BMS, Regeneron, Almirall, Roche, and Sanofi. SM-A declares honoraria for lectures from MSD and BMS and an advisory role with MSD. BN declares honoraria for lectures from MSD (payment to institution) and travel support from MSD. ER declares consulting fees from Amgen, Bayer, BMS, Delcath, MSD, Merck, Novartis, and Pierre Fabre; honoraria from Amgen, BMS, MSD, Merck, Novartis, Pierre Fabre, and Sanofi; travel support from Amgen, BMS, MSD, Merck, Novartis, Pierre Fabre, Roche, and Sanofi; advisory roles with BMS, MSD, Novartis, and Pierre Fabre; board memberships with Austrian Cancer Aid and Austrian Cancer Aid/Styria; membership in Arbeitsgruppe Melanom Dermatoonkologie; stock in Roche Pharma; and institutional grants for clinical trials from Amgen, BMS, Delcath, Incyte, MSD, Merck, Novartis, Pfizer, Regeneron, Roche, and Sanofi. CR declares consulting fees from BMS, Roche, Pierre Fabre, Novartis, Sanofi, Pfizer, MSD, Merck, Sun Pharma, Ultimovacs, Regeneron, Egle, Philogen, and MAAT Pharma; honoraria from Pierre Fabre, Sanofi, BMS, MSD, and Novartis; travel support from Pierre Fabre; and participation on advisory boards for BMS, Roche, Pierre Fabre, Novartis, Sanofi, Pfizer, MSD, Merck, Sun Pharma, Ultimovacs, Regeneron, Egle, Philogen, and MAAT Pharma. DS declares grants or contracts to their institution from Amgen, BMS, MSD, and Pfizer; consulting fees from Philogen, InflaRx, Neracare, MSD, Novartis, BMS, Pfizer, Pierre Fabre, Replimune, Sun Pharma, Daiichi Sankyo, AstraZeneca, IQVIA, LabCorp, Ultimovacs, Seagen, Immunocore, Immatics, BioNTech, PamGene, BioAlta, Regeneron, Agenus, Erasca, Formycon, NoviGenix, CureVac, and Sanofi (all to himself); honoraria for lectures and presentations from Neracare, MSD, Novartis, BMS, Pierre Fabre, Replimune, Sun Pharma, and Sanofi (all to himself); travel support from Pierre Fabre; advisory roles with Immunocore, AstraZeneca, BioAlta, Daiichi Sankyo, InflaRx, and Replimune (all to himself); and leadership roles with the European Organisation for the Research and Treatment of Cancer Melanoma Group steering board, DeCOG steering board, Nationale Versorgungskonferenz Hautkrebs (NVKH) chair, and Comprehensive Cancer Center (Essen) chair (all unpaid). RS declares an investigator grant from the National Health and Medical Research Council of Australia; consulting fees from F Hoffmann-La Roche, MetaOptima Technology, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, MSD, NeraCare, Amgen, BMS, Myriad Genetics, GSK, IO Biotech, and SkylineDX; and a submitted patent application for methods related to identifying skin cancer, administering biopsies, and treating skin cancer. VKS declares grants or contracts from Neogene Therapeutics, Skyline Dx, and Turnstone Biologics, and consulting fees from BMS, Genesis Drug Discovery & Development, Helix Biopharma, Iovance, Merck, Mural Oncology, Novartis, and Sun Pharma. AW declares honoraria for lectures, presentations, and speakers bureaus from BMS and MSD and participation on data safety monitoring boards or advisory boards for BMS, MSD, and Novartis. MW declares consulting fees from BMS, MSD, Novartis, Pierre Fabre, Regeneron, and Roche and honoraria for lectures and presentations from BMS, MSD, and Pierre Fabre. All other authors declare no competing interests.